Distributors and Partner Labs

CountryAffiliationCompany NameCompany AddressWebsiteContact Details
AustraliaDistributorJomar Life Research1 Dalmore Drive Caribbean
Park Scoresby
Victoria 3179
www.jlresearch.com.au[email protected]
AustriaDistributor, Partner LabAIT Austrian Institute of TechnologyGiefinggasse 4,
1210 Vienna – Austria
FN:115980 i HG Wien
www.ait.ac.at[email protected]
ChinaDistributor, Partner LabShanghai Universal Biotech Co. LtdBuilding No.16, New Wealth Park
No.15, Gudan Road
Shanghai, China
www.univ-bio.com[email protected]
SingaporeDistributorProbioscience Technologies Pte Ltd62 Ubi Road 1, #08-22
Oxley Bizhub 2,
Singapore 408734
www.probioscience.org[email protected]
South KoreaDistributorDAWINBIO Inc.601, ITECO, 150, Jojeong-daero, Hanam City,
Gyeonggi-do, Korea
www.dawinbio.com[email protected]
TaiwanDistributorAllBio Corporation5F., No. 357, Sec. 3,
Yifeng Rd., Nantun Dist.,
Taichung City 40880, Taiwan
www.allbio.com.tw[email protected]
UAEDistributorLifetastic FZ LLCDubai Science Park
PO Box 75344 Dubai-UAE
www.lifetastichealth.com[email protected]
US, Canada, EUsengenicsWe sell direct. Please submit your enquiry herewww.sengenics.com
USADistributor, Partner LabHouston Omics Collaborative at the University of Houston3517 Cullen Blvd, Rm 2027
SERC, Biomedical Engineering Dept
Houston, TX, 77204
hoc.bme.uh.edu[email protected]


Protein Array

sero-profiling platform

Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Protein Array

Flexible format for
high-throughput screening

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

2008 – 2019 © Sengenics All rights reserved